Abstract
Liposome-encapsulated drugs often exhibit reduced toxicity and have also been shown to enhance retention of drugs in the tissues. Thus, encapsulation of drugs in liposomes has often resulted in an improved overall therapeutic efficacy. The results of efficacy of liposome-encapsulated ciplofloxacin or azithromycin for therapy of intracellular M. avium infection show enhanced cellular delivery of liposome-encapsulated antibiotics and suggest that efficiency of intracellular targeting is sufficient to mediate enhanced antimycobacterial effects. The antitubercular drugs encapsulated in lung specific stealth liposomes have enhanced efficacies against tuberculosis infection in mice. These results from stealth liposome study indicate that antitubercular drugs encapsulated in liposome may provide therapeutic advantages over the existing chemotherapeutic regimen for tuberculosis. Liposomes with encapsulated amikacin are able to protect collagen almost completely from adherence of bacterial cells of all strains examined and prevent from invading of bacteria.
Keywords: anti-bacterial drug, anti-mycobacterial drug, mycobacterium avium infection, mycobacterium tuberculosis infection, staphylococcus aureus infection, pseudomonas aeruginosa
Current Pharmaceutical Design
Title: Design of Anti-Bacterial Drug and Anti-Mycobacterial Drug for Drug Delivery System
Volume: 8 Issue: 6
Author(s): Katsunori Yanagihara
Affiliation:
Keywords: anti-bacterial drug, anti-mycobacterial drug, mycobacterium avium infection, mycobacterium tuberculosis infection, staphylococcus aureus infection, pseudomonas aeruginosa
Abstract: Liposome-encapsulated drugs often exhibit reduced toxicity and have also been shown to enhance retention of drugs in the tissues. Thus, encapsulation of drugs in liposomes has often resulted in an improved overall therapeutic efficacy. The results of efficacy of liposome-encapsulated ciplofloxacin or azithromycin for therapy of intracellular M. avium infection show enhanced cellular delivery of liposome-encapsulated antibiotics and suggest that efficiency of intracellular targeting is sufficient to mediate enhanced antimycobacterial effects. The antitubercular drugs encapsulated in lung specific stealth liposomes have enhanced efficacies against tuberculosis infection in mice. These results from stealth liposome study indicate that antitubercular drugs encapsulated in liposome may provide therapeutic advantages over the existing chemotherapeutic regimen for tuberculosis. Liposomes with encapsulated amikacin are able to protect collagen almost completely from adherence of bacterial cells of all strains examined and prevent from invading of bacteria.
Export Options
About this article
Cite this article as:
Yanagihara Katsunori, Design of Anti-Bacterial Drug and Anti-Mycobacterial Drug for Drug Delivery System, Current Pharmaceutical Design 2002; 8 (6) . https://dx.doi.org/10.2174/1381612023395808
DOI https://dx.doi.org/10.2174/1381612023395808 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Based Drug Discovery Accelerated by Many-Core Devices
Current Drug Targets The Impact of Proteomic Advances on Bacterial Gene Annotation
Current Proteomics Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Importance of a Potential Salt Bridge and Hydrophobic Core in the Function and Oligomerization of a Small Heat Shock Protein
Protein & Peptide Letters An Approach for the Rational Design of New Antituberculosis Agents
Current Drug Targets Artificial Neural Networks to Optimize Formulation Components of a Fixed- Dose Combination of Rifampicin, Isoniazid and Pyrazinamide in a Microemulsion
Current Drug Discovery Technologies Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents
Current Pharmaceutical Design Effects of Chrisotherapeutic Gold Compounds on Prostaglandin E2 Production
Current Drug Targets - Inflammation & Allergy An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmaniasis (VL)
Current Drug Targets Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets Recent Patents Regarding Essential Oils and the Significance of their Constituents in Human Health and Treatment
Recent Patents on Anti-Infective Drug Discovery Opportunities and Challenges for Niosomes as Drug Delivery Systems
Current Drug Delivery Recent Development and Future Perspective of Antitubercular Therapy
Anti-Infective Agents in Medicinal Chemistry Review of Common Sequence Alignment Methods: Clues to Enhance Reliability
Current Genomics Multidisciplinary Study on Immigrants African and Asian Children’s Health: Socio-Cultural Factors Influencing Breastfeeding
Current Women`s Health Reviews Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology